

# Genomewide association for schizophrenia in the CATIE study: results of stage 1

PF Sullivan, D Lin, J-Y Tzeng, E van den Oord, D Perkins, TS Stroup, M Wagner, S Lee, FA Wright, F Zou, W Liu, AM Downing, J Lieberman and SL Close

*Molecular Psychiatry* (2009) **14**, 1144; doi:10.1038/mp.2008.74

**Correction to:** *Molecular Psychiatry* (2008) **13**, 570–584; doi: 10.1038/mp.2008.25 For technical reasons, Supplementary Tables 2, 3 and 4 were not published online. They now appear online at [www.nature.com/mp](http://www.nature.com/mp).

Supplementary Information accompanies the paper on the *Molecular Psychiatry* website (<http://www.nature.com/mp>)

# Clearance mechanisms of Alzheimer's amyloid- $\beta$ peptide: implications for therapeutic design and diagnostic tests

KA Bates, G Verdile, Q-X Li, D Ames, P Hudson, CL Masters and RN Martins

*Molecular Psychiatry* (2009) **14**, 1144; doi:10.1038/mp.2008.123

**Correction to:** *Molecular Psychiatry* (2009) **14**, 469–486; doi: 10.1038/mp.2008.96 Following the publication of the above article, the authors noted errors in Table 1. The revised table appears below:

**Table 1** Soluble (aqueous buffer soluble) and insoluble (aqueous buffer insoluble) A $\beta$  levels in human AD and control brains from a selection of publications

Study (reference)	Area measured	Sample	A $\beta$ ( $\mu$ g/g wet tissue)		Total A $\beta$	% Soluble	Methods
			Soluble	Insoluble			
Fonte <i>et al.</i> <sup>24a</sup>	Frontal cortex	Control (14)	(Not determined)		0.1 $\pm$ 0.1		WB (WO2)
		AD (17)	1.11	9.99	11.1 $\pm$ 3.1	10	
McLean <i>et al.</i> <sup>26</sup>	Superior frontal gyrus	Control (18)	<0.1 $\pm$ 0.1	1.9 $\pm$ 2.5	2.0	<4.7	WB (WO2)
		AD (18)	0.3 $\pm$ 0.3	20.6 $\pm$ 11.1	20.1	1.4	
Lue <i>et al.</i> <sup>25b</sup>	Superior frontal gyrus	Control (8)	0.003 $\pm$ 0.002	13.0 $\pm$ 5.9	13.0 $\pm$ 5.9	0.02	ELISA (R163/R165-4G8)
		Neurological control (8)	0.018 $\pm$ 0.008	116.4 $\pm$ 13.2	116.4 $\pm$ 13.2	0.02	
Fodero-Tavoletti <i>et al.</i> <sup>27</sup>	Cerebral cortex	AD (8)	0.107 $\pm$ 0.024	247.0 $\pm$ 56.0	247.1 $\pm$ 56.0	0.04	ELISA (G210/G211-WO2)
		Control (3)	0.02 $\pm$ 0.0006	0.02 $\pm$ 0.003	0.04 $\pm$ 0.0	50	
Wang <i>et al.</i> <sup>28c</sup>	Cerebral cortex	AD (3)	0.55 $\pm$ 0.17	4.9 $\pm$ 1.5	5.4	10.2	ELISA (BAN50-BA27/BC05)
		Control (10)	0.009	0.009	0.02	45	
Hellstrom-Lindahl <i>et al.</i> <sup>29b</sup>	Frontal cortex	Neurological control (10)	0.14	5.0	2.7	5.1	ELISA (Signal select Biosource)
		AD (23)	2.8	9.5	12.3	22.7	
Li <i>et al.</i> <sup>30d</sup>	Temporal cortex	Controls (10)	0.00 $\pm$ 0	0.0007 $\pm$ 0.0001	0.0007 $\pm$ 0.0001	0	ELISA (Biosource, 4G8)
		AD (7)	0.0002 $\pm$ 0.00	0.0035 $\pm$ 0.0007	0.0037	5.4	
		Controls (7)	0	<0.0019	<0.0059	0	
		AD (7)	0.049–0.107	0.492–0.813	0.599 $\pm$ 0.257	8.2	

Abbreviations: A $\beta$ , amyloid- $\beta$ ; AD, Alzheimer's disease; ELISA, enzyme-linked immunosorbent assay; WB, western blot.

The sample size from each paper is given in parentheses in the sample column, and the antibody used is given in parentheses in the methods column, values presented as mean  $\pm$  s.e.m. (except for where noted).

<sup>a</sup>Values reported as  $\mu$ g/g total protein rather than  $\mu$ g/g wet tissue.

<sup>b</sup>Combined A $\beta$ 40 and A $\beta$ 42 values for the soluble and insoluble pool.

<sup>c</sup>Soluble designated as A $\beta$ 40, insoluble as A $\beta$ 42.

<sup>d</sup>Values converted to  $\mu$ g/g total protein using the molecular weight of A $\beta$ 40 and presented as the range.